BANK VONTOBEL/CALL/BIOGEN IDEC/320/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 19:03:33 07/06/2024 BST | ||
| 0.105 EUR | -16.00% |
|
| Current month | +26.26% | ||
| 1 month | -8.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 0.105 | -16.00% |
| 06/06/24 | 0.125 | -21.88% |
| 05/06/24 | 0.16 | +5.26% |
| 04/06/24 | 0.152 | +20.63% |
| 03/06/24 | 0.126 | +27.27% |
Delayed Quote Deutsche Boerse AG
Last update June 07, 2024 at 07:03 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM36AT |
| ISIN | DE000VM36AT0 |
| Date issued | 18/10/2023 |
| Strike | 320 $ |
| Maturity | 20/09/2024 (105 Days) |
| Parity | 10 : 1 |
| Emission price | 1.91 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.23 € |
|---|---|
| Lowest since issue | 0.009 € |
| Spread | 0.021 € |
| Spread % | 20.00% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
225.4
USD
Average target price
284.6
USD
Spread / Average Target
+26.27%
- Stock Market
- Warrants
- Warrant